Guido Grassi1, Gino Seravalle2, Fosca Quarti Trevano3, Domenico Spaziani4, Filippo Scalise5, Carla Auguadro5, Patrizia Pizzini6, Giovanni Tripepi6, Graziella D'Arrigo6, Francesca Mallamaci6, Giuseppe Mancia2, Carmine Zoccali6. 1. Clinica Medica, Dipartimento di Scienze della Salute, Università Milano-Bicocca, Milan, Italy; IRCCS Multimedica, Sesto San Giovanni, Milan, Italy; 2. Istituto Auxologico Italiano, Milan, Italy; 3. Clinica Medica, Dipartimento di Scienze della Salute, Università Milano-Bicocca, Milan, Italy; 4. Unità Operativa di Cardiologia, Ospedale Magenta, Milan, Italy; 5. Cardiologia Interventistica, Policlinico di Monza, Monza, Italy; and. 6. CNR-IFC, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Reggio Calabria, Italy.
Abstract
BACKGROUND AND OBJECTIVES: The plasma concentration of the endogenous inhibitor of nitric oxide synthase asymmetric dimethylarginine (ADMA) associates with sympathetic activity in patients with CKD, but the driver of this association is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this longitudinal study (follow-up: 2 weeks-6 months), repeated measurements over time of muscle sympathetic nerve activity corrected (MSNAC), plasma levels of ADMA and symmetric dimethylarginine (SDMA), and BP and heart rate were performed in 14 patients with drug-resistant hypertension who underwent bilateral renal denervation (enrolled in 2013 and followed-up until February 2014). Stability of ADMA, SDMA, BP, and MSNAC over time (6 months) was assessed in two historical control groups of patients maintained on stable antihypertensive treatment. RESULTS: Time-integrated changes in MSNAC after renal denervation ranged from -40.6% to 10% (average, -15.1%), and these changes were strongly associated with the corresponding changes in plasma ADMA (r= 0.62, P=0.02) and SDMA (r=0.72, P=0.004). Changes in MSNAC went along with simultaneous changes in standardized systolic (r=0.65, P=0.01) and diastolic BP (r=0.61, P=0.02). In the historical control groups, no change in ADMA, SDMA, BP, and MSNAC levels was recorded during a 6-month follow-up. CONCLUSIONS: In patients with resistant hypertension, changes in sympathetic activity after renal denervation associate with simultaneous changes in plasma levels of the two major endogenous methylarginines, ADMA and SDMA. These observations are compatible with the hypothesis that the sympathetic nervous system exerts an important role in modulating circulating levels of ADMA and SDMA in this condition.
BACKGROUND AND OBJECTIVES: The plasma concentration of the endogenous inhibitor of nitric oxide synthase asymmetric dimethylarginine (ADMA) associates with sympathetic activity in patients with CKD, but the driver of this association is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this longitudinal study (follow-up: 2 weeks-6 months), repeated measurements over time of muscle sympathetic nerve activity corrected (MSNAC), plasma levels of ADMA and symmetric dimethylarginine (SDMA), and BP and heart rate were performed in 14 patients with drug-resistant hypertension who underwent bilateral renal denervation (enrolled in 2013 and followed-up until February 2014). Stability of ADMA, SDMA, BP, and MSNAC over time (6 months) was assessed in two historical control groups of patients maintained on stable antihypertensive treatment. RESULTS: Time-integrated changes in MSNAC after renal denervation ranged from -40.6% to 10% (average, -15.1%), and these changes were strongly associated with the corresponding changes in plasma ADMA (r= 0.62, P=0.02) and SDMA (r=0.72, P=0.004). Changes in MSNAC went along with simultaneous changes in standardized systolic (r=0.65, P=0.01) and diastolic BP (r=0.61, P=0.02). In the historical control groups, no change in ADMA, SDMA, BP, and MSNAC levels was recorded during a 6-month follow-up. CONCLUSIONS: In patients with resistant hypertension, changes in sympathetic activity after renal denervation associate with simultaneous changes in plasma levels of the two major endogenous methylarginines, ADMA and SDMA. These observations are compatible with the hypothesis that the sympathetic nervous system exerts an important role in modulating circulating levels of ADMA and SDMA in this condition.
Authors: Jan T Kielstein; Shelley R Salpeter; Stefanie M Bode-Boeger; John P Cooke; Danilo Fliser Journal: Nephrol Dial Transplant Date: 2006-06-09 Impact factor: 5.992
Authors: Guido Grassi; Gino Seravalle; Lorenzo Ghiadoni; Giovanni Tripepi; Rosa Maria Bruno; Giuseppe Mancia; Carmine Zoccali Journal: Clin J Am Soc Nephrol Date: 2011-09-22 Impact factor: 8.237
Authors: Dagmara Hering; Petra Marusic; Antony S Walton; Elisabeth A Lambert; Henry Krum; Krzysztof Narkiewicz; Gavin W Lambert; Murray D Esler; Markus P Schlaich Journal: Hypertension Date: 2014-04-14 Impact factor: 10.190
Authors: L Ghiadoni; A E Donald; M Cropley; M J Mullen; G Oakley; M Taylor; G O'Connor; J Betteridge; N Klein; A Steptoe; J E Deanfield Journal: Circulation Date: 2000-11-14 Impact factor: 29.690
Authors: Saskia J H Brinkmann; Myrte C de Boer; Nikki Buijs; Paul A M van Leeuwen Journal: Curr Opin Clin Nutr Metab Care Date: 2014-01 Impact factor: 4.294
Authors: Daniel de Oliveira Beraldo; Cássio J Rodrigues; Beata M R Quinto; Marcelo C Batista Journal: J Clin Hypertens (Greenwich) Date: 2020-11-08 Impact factor: 3.738